Pomerantz LLP Investigates Potential Securities Claims Against PepGen Inc.
On March 24, 2025, Pomerantz LLP, a leading securities law firm, announced that it is investigating potential securities claims on behalf of investors of PepGen Inc (“PepGen” or the “Company”) (NASDAQ: PEPG). The investigation concerns possible violations of the federal securities laws, specifically related to alleged misrepresentations and/or omissions in the Company’s securities filings and public statements.
Background on PepGen Inc.
PepGen is a clinical-stage biotechnology company focused on developing therapeutics for genetic disorders using its proprietary mRNA technology. The Company’s lead program is focused on developing gene therapies for Duchenne muscular dystrophy and other neuromuscular disorders.
The Investigation
According to the investigation notice issued by Pomerantz LLP, the investigation concerns allegations that PepGen may have issued materially misleading statements and/or failed to disclose material information to investors. Specifically, the notice alleges that the Company may have downplayed the risks associated with its clinical trials and/or overstated the potential market size for its lead product.
Impact on Individual Investors
For individual investors who purchased or otherwise acquired securities of PepGen between specific dates, this investigation could potentially result in significant financial losses. If it is determined that the Company engaged in securities fraud, shareholders may be entitled to recover their losses through a securities class action lawsuit.
Impact on the Biotech Industry
The investigation into PepGen is a reminder of the importance of transparency and accuracy in the biotech industry, particularly in the context of clinical trial data and market size projections. The outcome of this investigation could set a precedent for future securities fraud cases in the sector, potentially leading to increased scrutiny and regulatory oversight.
Conclusion
The investigation into potential securities claims against PepGen Inc is an ongoing process, and it remains to be seen what the ultimate outcome will be. However, for individual investors who may have purchased securities of the Company during the relevant timeframe, it is important to be aware of the potential risks and to consider seeking legal advice if they believe they have suffered financial losses as a result of any alleged misrepresentations or omissions. For the broader biotech industry, the outcome of this investigation could have significant implications, potentially leading to increased scrutiny and regulatory oversight.
- Pomerantz LLP is investigating potential securities claims against PepGen Inc.
- The investigation concerns allegations of misrepresentations and/or omissions in the Company’s securities filings and public statements.
- Individual investors who purchased securities of PepGen during a specific timeframe may be entitled to recover losses if securities fraud is proven.
- The outcome of this investigation could set a precedent for future securities fraud cases in the biotech sector.
